NASDAQ:BCLI

Brainstorm Cell Therapeutics Stock Insider Trading

etoro logo Buy BCLI
*Your capital is at risk
$0.770
-0.0217 (-2.74%)
At Close: Jun 03, 2026

Brainstorm Cell Therapeutics Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 98.01. In total, the insiders bought 6.74M and sold 126K BCLI shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power

(Last 100 transactions)
98.01
Buy 6.74M shares
Sell 126K shares
98% Buy Activity
Moderate Positive Correlation
Buy Signal High Confidence
Feb 26, 2026

Analysis Breakdown:

  • Strongly supported by a very high Insider Power Score of 98.01.
  • Partially supported by a positive historical correlation.
  • Confidence increased due to high data reliability score of 90.
  • Supported by overwhelming buy-side pressure (98% buys).

Historical Insider Trades

Date Type Person Role Amount
May 25, 2026
Buy
Stock Option (Right to Buy)
Pitts Peter Joe
Director
Director 150 000
Value: $102.0K
Feb 26, 2026
Buy
Common Stock
A-Award
Patlis Alla
See Remarks
Officer 100 000
Value: $66.0K
Feb 26, 2026
Buy
Common Stock
A-Award
Yablonka Uri
EVP & Chief Business Officer
Officer 150 000
Value: $99.0K
Feb 26, 2026
Buy
Common Stock
A-Award
Lebovits Chaim
President & CEO
CEO / President 1 800 000
Value: $1.19M
Feb 26, 2026
Buy
Common Stock
A-Award
Frenkel Jacob A
Director
Director 200 000
Value: $132.0K
Feb 26, 2026
Buy
Common Stock
A-Award
Arbel Irit
Director
Director 120 000
Value: $79.2K
Feb 26, 2026
Buy
Stock Option (Right to Buy)
A-Award
Hartounian Hartoun
Director
Director 225 000
Value: $157.5K
Feb 26, 2026
Buy
Stock Option (Right to Buy)
A-Award
Polverino Anthony J.
Director
Director 150 000
Value: $105.0K
Feb 26, 2026
Buy
Stock Option (Right to Buy)
A-Award
Bairu Menghisteab
Director
Director 150 000
Value: $105.0K
Feb 26, 2026
Buy
Stock Option (Right to Buy)
A-Award
Lindborg Stacy
Director
Director 150 000
Value: $105.0K
Feb 26, 2026
Buy
Stock Option (Right to Buy)
A-Award
Naor Nir
Director
Director 180 000
Value: $126.0K
Feb 26, 2026
Buy
Stock Option (Right to Buy)
A-Award
Dagher Ibrahim B.
Director
Director 225 000
Value: $157.5K
Jan 01, 2025
Buy
Common Stock
A-Award
Dagher Ibrahim B.
Chief Medical Officer
Officer 50 000
Value: $38.5K
Jan 01, 2025
Buy
Common Stock
A-Award
Dagher Ibrahim B.
Chief Medical Officer
Officer 50 000
Value: $38.5K
Jan 01, 2025
Buy
Common Stock
A-Award
Lebovits Chaim
President & CEO
CEO / President 120 000
Value: $92.4K
Jan 01, 2025
Buy
Common Stock
A-Award
Frenkel Jacob A
Director
Director 40 000
Value: $30.8K
Jan 01, 2025
Buy
Common Stock
A-Award
Polverino Anthony J.
Director
Director 24 000
Value: $18.5K
Jan 01, 2025
Buy
Common Stock
A-Award
Yablonka Uri
EVP & Chief Business Officer
Officer 20 000
Value: $15.4K
Jan 01, 2025
Buy
Common Stock
A-Award
Yablonka Uri
EVP & Chief Business Officer
Officer 40 000
Value: $30.8K
Jan 01, 2025
Buy
Common Stock
A-Award
Patlis Alla
See Remarks
Officer 40 000
Value: $30.8K
Jan 01, 2025
Buy
Common Stock
A-Award
Naor Nir
Director
Director 30 666
Value: $23.6K
Jan 01, 2025
Buy
Common Stock
A-Award
Lindborg Stacy
Director
Director 20 000
Value: $15.4K
Jan 01, 2025
Buy
Common Stock
A-Award
Hartounian Hartoun
EVP, Chief Operating Officer
C-Suite Officer 50 000
Value: $38.5K
Jan 01, 2025
Buy
Common Stock
A-Award
Bairu Menghisteab
Director
Director 24 000
Value: $18.5K
Jan 01, 2025
Buy
Common Stock
A-Award
Arbel Irit
Director
Director 30 666
Value: $23.6K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

Click to get the best stock tips daily for free!
ABOUT BRAINSTORM CELL THERAPEUTICS INC.
Brainstorm Cell Therapeutics
Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative ...
GOLDEN STAR
Ticker Change Signal Date
LITE
$905.00
3.65% Jun 01
RUN
$12.83
15.74% May 06
GLBE
$31.61
0.569% May 05
SAP
$172.39
4.80% May 05
ADBE
$243.57
5.20% Apr 29

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE